OncoMatch/Clinical Trials/NCT02747303
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
Is NCT02747303 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for brain metastases.
This is a randomized study to determine if not treating planning target volume (PTV) margins during radiation therapy worsens progression free survival rates in patients with brain metastases.
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: cranial radiotherapy
Exception: allowed if >90 days before enrollment
Prior cranial radiotherapy within 90 days of trial enrollment
Cannot have received: stereotactic radiosurgery
Exception: allowed if not to any lesion to be treated on protocol
prior SRS at any time to any lesion to be treated on protocol
Cannot have received: chemotherapy
Exception: allowed if >14 days before SRS
Chemotherapy (including oral agents and targeted agents) given within 14 days of SRS
Cannot have received: immunotherapy
Exception: allowed if >14 days before SRS
immunotherapy given within 14 days of SRS
Cannot have received: anti-HER2 therapy
Exception: allowed if >14 days before SRS
For Her2+ breast cancer patients, anti-Her2 therapy cannot be given within 14 days of SRS
Cannot have received: antibody-drug conjugate (trastuzumab emtansine)
Exception: patients scheduled to receive trastuzumab emtansine after SRS cannot be enrolled
Patients who are scheduled to receive trastuzumab emtansine after SRS cannot be enrolled
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Chicago · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify